| scholarly article | Q13442814 |
| P2093 | author name string | Geoffrey K Dube | |
| Ibrahim Batal | |||
| Demetra Tsapepas | |||
| Lloyd Ratner | |||
| Russell J Crew | |||
| Rita Leal | |||
| P2860 | cites work | Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients | Q24246340 |
| What is the best way to measure renal fibrosis?: A pathologist’s perspective | Q26796641 | ||
| A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients | Q27000107 | ||
| Drug-induced glomerular disease: direct cellular injury | Q27692666 | ||
| Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data | Q31004418 | ||
| Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction. | Q31108592 | ||
| Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? | Q33346767 | ||
| Nephrotoxic aspects of cyclosporine | Q33360112 | ||
| De novo thrombotic microangiopathy following treatment with sirolimus: report of two cases | Q33364407 | ||
| Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy | Q33366519 | ||
| Thrombotic microangiopathy after kidney transplantation | Q33372586 | ||
| De novo thrombotic microangiopathy. An underrated complication of renal transplantation | Q33375722 | ||
| Gene Expression in Biopsies of Acute Rejection and Interstitial Fibrosis/Tubular Atrophy Reveals Highly Shared Mechanisms That Correlate With Worse Long-Term Outcomes. | Q33885388 | ||
| Calcineurin inhibitor nephrotoxicity | Q34945314 | ||
| The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine | Q35588481 | ||
| Cyclosporine nephrotoxicity: how does it affect renal allograft function and transplant morphology? | Q35711160 | ||
| Chronic progressive calcineurin nephrotoxicity: an overstated concept | Q35929301 | ||
| Immunosuppressive drugs for kidney transplantation. | Q35992328 | ||
| Primer: Histopathology of calcineurin-inhibitor toxicity in renal allografts | Q36577199 | ||
| Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update | Q36703450 | ||
| New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone. | Q36788871 | ||
| Oxidative stress as a common pathway to chronic tubulointerstitial injury in kidney allografts | Q36802004 | ||
| High-dosage intravenous immunoglobulin-associated macrovacuoles are associated with chronic tubulointerstitial lesion worsening in renal transplant recipients | Q36843406 | ||
| Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes | Q37092612 | ||
| Morphology of cyclosporine nephrotoxicity in the rat | Q69510157 | ||
| Cyclosporine-associated chronic nephropathy | Q70376376 | ||
| Cyclosporine A induced arteriolopathy in a rat model of chronic cyclosporine nephropathy | Q71754644 | ||
| Evaluation of chronic renal disease in heart transplant recipients: importance of pretransplantation native kidney histologic evaluation | Q72130385 | ||
| The side-effects of ciclosporine-A and tacrolimus | Q77059728 | ||
| Acute rejection in non-compliant renal allograft recipients: a distinct morphology | Q80291152 | ||
| Is sirolimus a nephrotoxic drug? A report of five cases | Q80502273 | ||
| A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis | Q80796893 | ||
| High sirolimus levels may induce focal segmental glomerulosclerosis de novo | Q80797353 | ||
| Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy | Q84870337 | ||
| Histological characteristics of calcineurin inhibitor toxicity--there is no such thing as specificity! | Q84870341 | ||
| mToR inhibitors-induced proteinuria: mechanisms, significance, and management | Q37218125 | ||
| Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm | Q37619991 | ||
| Influence of tacrolimus metabolism rate on renal function after solid organ transplantation | Q37662992 | ||
| mTOR inhibitor-associated proteinuria in kidney transplant recipients | Q37964271 | ||
| Current treatment strategies for inhibiting mTOR in cancer | Q38286529 | ||
| Regulation of innate immune cell function by mTOR. | Q38592317 | ||
| Targeting mTOR Signaling Can Prevent the Progression of FSGS. | Q38922365 | ||
| Renal transplant immunology in the last 20 years: A revolution towards graft and patient survival improvement | Q38967258 | ||
| Immunosuppression for kidney transplantation: Where are we now and where are we going? | Q39199396 | ||
| Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins. | Q39583588 | ||
| Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras | Q39680835 | ||
| KDIGO clinical practice guideline for the care of kidney transplant recipients | Q39936865 | ||
| Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy | Q40025515 | ||
| Response of human renal tubular cells to cyclosporine and sirolimus: a toxicogenomic study | Q40115041 | ||
| Banff 07 classification of renal allograft pathology: updates and future directions | Q40121163 | ||
| Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells | Q41743877 | ||
| Inhibition of MTOR disrupts autophagic flux in podocytes | Q41812610 | ||
| Sirolimus and kidney growth in autosomal dominant polycystic kidney disease | Q43004251 | ||
| Apoptosis and adaptive responses to oxidative stress in human endothelial cells exposed to cyclosporin A correlate with BCL-2 expression levels | Q43548109 | ||
| Chronic calcineurin inhibitor nephrotoxicity-lest we forget | Q43759235 | ||
| Chronic cyclosporin nephropathy: long-term effects of cyclosporin on renal allografts | Q43854944 | ||
| Sirolimus may promote thrombotic microangiopathy | Q44326132 | ||
| Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. | Q44378937 | ||
| Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience | Q44437921 | ||
| Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination | Q44899011 | ||
| Isometric tubular epithelial vacuolization in renal allograft biopsy specimens of patients receiving low-dose intravenous immunoglobulin for a positive crossmatch | Q45077070 | ||
| Rapamycin for focal segmental glomerulosclerosis: a report of 3 cases | Q46079811 | ||
| The TSC-mTOR signaling pathway regulates the innate inflammatory response | Q46321173 | ||
| Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys | Q46702750 | ||
| Post-transplantation proteinuria and sirolimus | Q46799640 | ||
| Proteinuria following a switch from calcineurin inhibitors to sirolimus | Q46825307 | ||
| Conversion from cyclosporine to sirolimus in stable renal transplant recipients | Q46863642 | ||
| Hyalinosis Lesions in Renal Transplant Biopsies: Time-Dependent Complexity of Interpretation | Q48206489 | ||
| Is arteriolar vacuolization a predictor of calcineurin inhibitor nephrotoxicity? | Q50534139 | ||
| NFATc3 regulates Kv2.1 expression in arterial smooth muscle. | Q50795101 | ||
| Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven. | Q50880766 | ||
| Collapsing glomerulopathy in a renal transplant recipient: potential molecular mechanisms. | Q51443976 | ||
| The evolution of nonimmune histological injury and its clinical relevance in adult-sized kidney grafts in pediatric recipients. | Q51740341 | ||
| Reproducibility studies on arteriolar hyaline thickening scoring in calcineurin inhibitor-treated renal allograft recipients. | Q53003709 | ||
| International variation in histologic grading is large, and persistent feedback does not improve reproducibility. | Q53301318 | ||
| Cyclosporine-induced interstitial fibrosis and arteriolar TGF-beta expression with preserved renal blood flow. | Q54067569 | ||
| Effect of cyclosporine administration on renal hemodynamics in conscious rats. | Q54441851 | ||
| Activation of NFATc3 Down-regulates the β1 Subunit of Large Conductance, Calcium-activated K+Channels in Arterial Smooth Muscle and Contributes to Hypertension | Q57396496 | ||
| Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study | Q57943257 | ||
| The Banff 97 working classification of renal allograft pathology | Q59314413 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pathology | Q7208 |
| sirolimus | Q32089 | ||
| nephrology | Q177635 | ||
| kidney transplantation | Q740909 | ||
| P304 | page(s) | 281-290 | |
| P577 | publication date | 2018-03-01 | |
| P1433 | published in | KI reports | Q27727507 |
| P1476 | title | Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation | |
| P478 | volume | 3 |
Search more.